A Phase III Randomised, Double-Blind Trial To Evaluate The Effect Of 12 Weeks Treatment Of Once Daily Empaglifozin 10mg Compared With Placebo On Exercise Ability And Heart Failure Symptoms, In Patients With Chronic Heart Failure With Reduced Ejection Fraction (Hfref) (EMPERIAL – Reduced)

Nicholls, Stephen (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Reference Number: HREC/50043/SVHM-2019-164332(v3)
NMA SSA Reference Number: SSA/50043/MonH-2019-169531(v1)
Monash Health Ref: RES-19-0000-245X

Status	Active
Effective start/end date	4/04/19 → 3/04/24

View all

View less

Keywords

clinical trial
phase 3 study
treatment efficacy
heart disease